{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:02:35Z","timestamp":1780513355912,"version":"3.54.1"},"reference-count":65,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010949","name":"The Copenhagen Trial Unit","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/501100010949","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,1,8]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the beneficial and harmful effects of duloxetine versus \u2018active placebo\u2019, placebo or no intervention for adults with major depressive disorder.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review with meta-analysis and trial sequential analysis of randomised trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Cochrane Central Register of Controlled Trials, MEDLINE, Embase, PsycINFO and other relevant databases up until January 2023. We requested clinical study reports from 36 competent authorities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria for selecting studies<\/jats:title>\n                    <jats:p>All randomised clinical trials comparing duloxetine versus placebo, \u2018active placebo\u2019 or no intervention, irrespective of publication type, publication status, publication year and language for treatment of major depressive disorder in adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Five authors in pairs extracted data using a standardised data extraction sheet. A third review author was consulted for disagreements. Intervention effects were assessed by both random-effects and fixed-effect model meta-analyses, risk of bias assessments were performed by two independent review authors using Cochrane\u2019s risk of bias tool V.2 and the certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We included 28 trials randomising a total of 7872 participants. All results were at high risk of bias. The trials\u2019 assessment time points were between 6 and 16 weeks after randomisation. Meta-analyses showed evidence of a beneficial effect of duloxetine on depressive symptoms (mean difference \u22121.81, Hamilton Depression Rating Scale (HDRS-17) points; 95% CI \u22122.34 to \u22121.28; heterogeneity I\n                      <jats:sup>2<\/jats:sup>\n                      =0.0%; 12 trials) and quality of life (mean difference \u22123.79 points, 95%\u2009CI \u22125.11 to \u22122.46; I\n                      <jats:sup>2<\/jats:sup>\n                      =0.0%; three trials), but the effect sizes were below our predefined minimal clinically important differences. Trial sequential analysis showed that we did not have enough information to assess the effects of duloxetine on serious adverse events (SAEs) (OR 0.67, 95%\u2009CI 0.44 to 1.02; I\n                      <jats:sup>2<\/jats:sup>\n                      =0.0%; 19 trials) or suicide or suicide attempts (OR 1.08, 95%\u2009CI 0.37 to 3.16; six trials). Duloxetine increased the risk of non-SAEs (risk ratio 1.27, 95%\u2009CI 1.22 to 1.32; I\n                      <jats:sup>2<\/jats:sup>\n                      =73.0%; 24 trials). The adverse events with the lowest number needed to harm (NNH) were nausea (NNH 6), dry mouth (NNH 13), somnolence (NNH 17), withdrawal syndrome (NNH 19), sweating (NNH 20), dizziness (NNH 21) and constipation (NNH 21).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Duloxetine appears to reduce depressive symptom scores and improve quality of life scores in the short term, but the effect sizes are minimal and of questionable patient importance. The short- and long-term effects of duloxetine on risks of SAEs and suicidality are uncertain. Duloxetine increases the risks of several short-term adverse events. Systematic assessments of benefits and harms over longer periods are required.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>PROSPERO 2016 CRD42016053931.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-082853","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T22:55:47Z","timestamp":1738968947000},"page":"e082853","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Beneficial and harmful effects of duloxetine versus placebo, \u2018active placebo\u2019 or no intervention for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8358-6259","authenticated-orcid":false,"given":"Faiza","family":"Siddiqui","sequence":"first","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital \u2500 Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9837-1958","authenticated-orcid":false,"given":"Johanne Juul","family":"Petersen","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital \u2500 Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6171-2904","authenticated-orcid":false,"given":"Sophie","family":"Juul","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital \u2500 Rigshospitalet, Copenhagen, Denmark"},{"name":"Stolpegaard Psychotherapy Centre, Mental Health Services, The Capital Region, Gentofte, Denmark"},{"name":"Department of Psychology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7756-4694","authenticated-orcid":false,"given":"Caroline Barkholt","family":"Kamp","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital \u2500 Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Regional Health Research, The Faculty of Heath Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-3660","authenticated-orcid":false,"given":"Marija","family":"Barbateskovic","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital \u2500 Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1214-6974","authenticated-orcid":false,"given":"Joanna","family":"Moncrieff","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"},{"name":"Research and Development Department, North East London NHS Foundation Trust (NELFT), Essex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1318-2029","authenticated-orcid":false,"given":"Mark Abie","family":"Horowitz","sequence":"additional","affiliation":[{"name":"Research and Development Department, North East London NHS Foundation Trust (NELFT), Essex, UK"},{"name":"(honorary position for MAH) Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Maagaard","sequence":"additional","affiliation":[{"name":"Centre for Anaesthesiological Research, Department of Anaesthesiology, Zealand University Hospital, K\u00f8ge, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran Kumar","family":"Katakam","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital \u2500 Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8861-0799","authenticated-orcid":false,"given":"Christian","family":"Gluud","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital \u2500 Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Regional Health Research, The Faculty of Heath Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janus C","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Copenhagen Trial Unit, Centre for Clinical Intervention Research, The Capital Region, Copenhagen University Hospital \u2500 Rigshospitalet, Copenhagen, Denmark"},{"name":"Department of Regional Health Research, The Faculty of Heath Sciences, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"2025121605232504000_15.2.e082853.1","unstructured":"American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders (DSM\u20135), Available: https:\/\/dsm.psychiatryonline.org\/dsmPreviousEditions"},{"key":"2025121605232504000_15.2.e082853.2","unstructured":"World Health Organization . Depression, Available: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/depression"},{"key":"2025121605232504000_15.2.e082853.3","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14m09298"},{"key":"2025121605232504000_15.2.e082853.4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/acps.12301","article-title":"Quality of life in major depressive disorder before\/after multiple steps of treatment and one-year follow-up","volume":"131","author":"IsHak","year":"2015","journal-title":"Acta Psychiatr Scand"},{"key":"2025121605232504000_15.2.e082853.5","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2147\/NDT.S159276","article-title":"Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study","volume":"14","author":"Saragoussi","year":"2018","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2025121605232504000_15.2.e082853.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.3826."},{"key":"2025121605232504000_15.2.e082853.7","doi-asserted-by":"publisher","DOI":"10.1037\/a0038550"},{"key":"2025121605232504000_15.2.e082853.8","unstructured":"Federal Drug Authority . Duloxetine (marketed as Cymbalta) Information, Available: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/duloxetine-marketed-cymbalta-information"},{"key":"2025121605232504000_15.2.e082853.9","unstructured":"European Medical Association . Cymbalta-epar-product-information, Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cymbalta-epar-product-information_en.pdf"},{"key":"2025121605232504000_15.2.e082853.10","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/31.1.96"},{"key":"2025121605232504000_15.2.e082853.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12888-016-1173-2","article-title":"Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder. A systematic review with meta-analysis and Trial Sequential Analysis","volume":"17","author":"Jakobsen","year":"2017","journal-title":"BMC Psychiatry"},{"key":"2025121605232504000_15.2.e082853.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32802-7"},{"key":"2025121605232504000_15.2.e082853.13","doi-asserted-by":"publisher","DOI":"10.1159\/000501215"},{"key":"2025121605232504000_15.2.e082853.14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13643-021-01722-5","article-title":"Duloxetine versus \u2018active\u2019 placebo, placebo or no intervention for major depressive disorder; a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis","volume":"10","author":"Siddiqui","year":"2021","journal-title":"Syst Rev"},{"key":"2025121605232504000_15.2.e082853.15","unstructured":"PRISMA 2020, 2024."},{"key":"2025121605232504000_15.2.e082853.16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56"},{"key":"2025121605232504000_15.2.e082853.17","unstructured":"National Institute for Clinical Excellence . Depression: Management of Depression in Primary and Secondary Care. Clinical Practice Guideline no 23. 2004."},{"key":"2025121605232504000_15.2.e082853.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmjebm-2020-111600"},{"key":"2025121605232504000_15.2.e082853.19","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use . ICH Harmonised Guideline: Integrated Addemdum to ICH E6(R1): Guideline for Good Clinical Practice (ICH-GCP), Available: https:\/\/ichgcp.net\/"},{"key":"2025121605232504000_15.2.e082853.20","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025121605232504000_15.2.e082853.21","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025121605232504000_15.2.e082853.22","unstructured":"RStudio . RStudio: Integrated Development for R. 2020. Available: http:\/\/www.rstudio.com"},{"key":"2025121605232504000_15.2.e082853.23","doi-asserted-by":"crossref","unstructured":"Higgins JPT , Thomas J , Chandler J , et al . Cochrane handbook for systematic reviews of interventions, 2nd edn (Cochrane book series). John Wiley & Sons, 2019.","DOI":"10.1002\/9781119536604"},{"key":"2025121605232504000_15.2.e082853.24","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-14-120","article-title":"Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods","volume":"14","author":"Jakobsen","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2025121605232504000_15.2.e082853.25","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s40263-022-00960-y","article-title":"Estimating Risk of Antidepressant Withdrawal from a Review of Published Data","volume":"37","author":"Horowitz","year":"2023","journal-title":"CNS Drugs"},{"key":"2025121605232504000_15.2.e082853.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.03.013"},{"key":"2025121605232504000_15.2.e082853.27","unstructured":"Thorlund K , Engstr\u00f8m J , Wetterslev J , et al . User manual for Trial Sequential Analysis (TSA), Available: www.ctu.dk\/tsa"},{"key":"2025121605232504000_15.2.e082853.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.10.007"},{"key":"2025121605232504000_15.2.e082853.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2011.11.008"},{"key":"2025121605232504000_15.2.e082853.30","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000018"},{"key":"2025121605232504000_15.2.e082853.31","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04592"},{"key":"2025121605232504000_15.2.e082853.32","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0407"},{"key":"2025121605232504000_15.2.e082853.33","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3956(02)00060-2"},{"key":"2025121605232504000_15.2.e082853.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2004.01.002"},{"key":"2025121605232504000_15.2.e082853.35","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000132448.65972.d9"},{"key":"2025121605232504000_15.2.e082853.36","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0309"},{"key":"2025121605232504000_15.2.e082853.37","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3283542457"},{"key":"2025121605232504000_15.2.e082853.38","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.761600"},{"key":"2025121605232504000_15.2.e082853.39","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3839-0"},{"key":"2025121605232504000_15.2.e082853.40","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2015.52"},{"key":"2025121605232504000_15.2.e082853.41","doi-asserted-by":"publisher","DOI":"10.1185\/030079906X167453"},{"key":"2025121605232504000_15.2.e082853.42","doi-asserted-by":"publisher","DOI":"10.1002\/hup.1262"},{"key":"2025121605232504000_15.2.e082853.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2006.03.004"},{"key":"2025121605232504000_15.2.e082853.44","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.164.6.900"},{"key":"2025121605232504000_15.2.e082853.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2013.01.019"},{"key":"2025121605232504000_15.2.e082853.46","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.clinthera.2009.07.006","article-title":"Desvenlafaxine 50 and 100 mg\/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies","volume":"31 Pt 1","author":"Tourian","year":"2009","journal-title":"Clin Ther"},{"key":"2025121605232504000_15.2.e082853.47","unstructured":"NIH . 6-week study treatment to evaluate the safety and effectiveness of AZD2066 in patients with major depressive disorder, NCT01145755 . 2012."},{"key":"2025121605232504000_15.2.e082853.48","first-page":"1613","article-title":"Clinical evaluation of duloxetine in the treatment of major depressive disorder placebo and paroxetine controlled double\u2010blind comparative study","volume":"12","author":"Kamijima","year":"2009","journal-title":"Japanese J Clin Psychopharmacol"},{"key":"2025121605232504000_15.2.e082853.49","unstructured":"Eli Lilly and Company . Randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced dose-finding study of Lu AA24530 in Major Depressive Disorder (11918A). Synopsis. 2010."},{"key":"2025121605232504000_15.2.e082853.50","unstructured":"Eli Lilly and Company . Validation of Daily Telephone Self-Assessment in the Study of Antidepressant Treatment Outcome (H8I-MC-HQAC). Clinical Study Summary. 2007."},{"key":"2025121605232504000_15.2.e082853.51","unstructured":"Eli Lilly and Company . A double-blind, placebo- and clomipramine-controlled study of duloxetine in patients with major depression (F1J-MC-HMAI). Abbreviated clinical study report. 2001."},{"key":"2025121605232504000_15.2.e082853.52","unstructured":"Eli Lilly and Company . Duloxetine versus Placebo in the Treatment of Major Depression (F1J-MC-HMAQ(B)). Clinical Study Report. 2001."},{"key":"2025121605232504000_15.2.e082853.53","unstructured":"Eli Lilly and Company . Duloxetine Versus Placebo and Paroxetine in the Acute Treatment of Major Depression (F1J-MC-HMAT), Clinical Study Report. 2001."},{"key":"2025121605232504000_15.2.e082853.54","unstructured":"Eli Lilly and Company . Duloxetine\/placebo in Major Depression (F1J-MC-HMAG). 1996."},{"key":"2025121605232504000_15.2.e082853.55","unstructured":"Eli Lilly and Company . Duloxetine 20\/30 mg vs. Placebo in Major Depression (F1J-MC-HMAH). Clinical Study Report. 1996."},{"key":"2025121605232504000_15.2.e082853.56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2012.12.001"},{"key":"2025121605232504000_15.2.e082853.57","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.12.2163"},{"key":"2025121605232504000_15.2.e082853.58","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3233\/JRS-200051","article-title":"Extensive selective reporting of quality of life in clinical study reports and publications of placebo-controlled trials of antidepressants","volume":"32","author":"Paludan-M\u00fcller","year":"2021","journal-title":"Int J Risk Saf Med"},{"key":"2025121605232504000_15.2.e082853.59","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.13m08443"},{"key":"2025121605232504000_15.2.e082853.60","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp12X658304"},{"key":"2025121605232504000_15.2.e082853.61","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jad.2018.10.357","article-title":"Tachyphylaxis in major depressive disorder: A review of the current state of research","volume":"245","author":"Kinrys","year":"2019","journal-title":"J Affect Disord"},{"key":"2025121605232504000_15.2.e082853.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.08.017"},{"key":"2025121605232504000_15.2.e082853.63","doi-asserted-by":"crossref","DOI":"10.1017\/S2045796019000520","article-title":"Persistent adverse effects of antidepressants","volume":"29","author":"Moncrieff","year":"2020","journal-title":"Epidemiol Psychiatr Sci"},{"key":"2025121605232504000_15.2.e082853.64","doi-asserted-by":"crossref","unstructured":"Lundh A , Lexchin J , Mintzes B , et al . Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;2. doi:10.1002\/14651858.MR000033.pub3","DOI":"10.1002\/14651858.MR000033.pub3"},{"key":"2025121605232504000_15.2.e082853.65","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2017.00275","article-title":"Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants\u2019 Efficacy and Harm","volume":"8","author":"Hengartner","year":"2017","journal-title":"Front Psychiatry"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-082853","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T13:23:37Z","timestamp":1765891417000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-082853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":65,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,7]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bmjopen-2023-082853"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-082853","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}